Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


What Is the Role for Antidepressants in Bipolar Disorder?

Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder.
Joseph F. Goldberg, MD
Greg Mattingly, MD
Released: October 5, 2021

In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.

Information on this Educational Activity


Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Joseph Goldberg, MD, has disclosed that he has received consulting fees from BioXcel, Lundbeck, Otsuka, and Sunovion and fees for non-CME/CE services from Allergan, Intercellular Therapies, and Sunovion.
Greg Mattingly, MD

Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
St Charles Psychiatry Associates
St Charles, Missouri

Greg Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Intra-Cellular Therapies

Related Content

Podcast from Clinical Care Options (CCO) with Drs Roger McIntyre and Sanjay J. Mathew on evidence-based approaches to choosing the right treatment for bipolar depression

Sanjay J. Mathew, MD Roger McIntyre, MD, FRCPC Released: November 30, 2021

Dr Greg Mattingly reviews the latest available clinical data for emerging diagnostic and therapy options for managing the mood disorders and TD, from Clinical Care Options (CCO)

Greg Mattingly, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: November 22, 2021 Expired: November 21, 2022

Clinical Care Options (CCO) commentary by Sanjay Gupta, MD, on choosing the right VMAT2 inhibitor for TD

Sanjay Gupta, MD Released: November 19, 2021

In this activity, a panel of Sanjay Gupta, MD reviews salient research studies of interest relevant to depression, schizophrenia, ADHD and substance abuse and provides clinical commentary

Sanjay Gupta, MD Released: November 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.